Bone marrow and tumor cell colony-forming units and human tumor xenograft efficacy of noncamptothecin and camptothecin topoisomerase I inhibitors

Molecular Cancer Therapeutics

Volumn 7, Issue 10, 2008, Pages 3212-3222

  Kurtzberg, Leslie S ^a   Battle, Traci ^a   Rouleau, Cecile ^a   Bagley, Rebecca G ^a   Agata, Naoki ^a   Yao, Min ^a   Schmid, Steven ^b   Roth, Stephanie ^b   Crawford, Jennifer ^b   Krumbholz, Roy ^b   Ewesuedo, Reginald ^b   Yu, Xian Jie ^a   Wang, Fei ^a   LaVoie, Edmond J ^c   Teicher, Beverly A ^a  

^a GENZYME CORPORATION   (United States)

^b GENZYME CORPORATION   (United States)

^c RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 8,9 DIMETHOXY 5 (2 N,N DIMETHYLAMINOETHYL) 2,3 METHYLENEDIOXY 5H DIBENZO[C,H][1,6]NAPHTHYRIDIN 6 ONE; ANTINEOPLASTIC AGENT; ARC 111; DOCETAXEL; GEMCITABINE; IRINOTECAN; TOPOTECAN; UNCLASSIFIED DRUG; CAMPTOTHECIN; DNA TOPOISOMERASE; DRUG DERIVATIVE; NAPHTHYRIDINE DERIVATIVE; TOPOVALE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW; COLON CARCINOMA; COLONY FORMING UNIT; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG SENSITIVITY; GRANULOCYTE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IC 50; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; MACROPHAGE; MALE; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; TUMOR CELL; TUMOR GROWTH; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; BODY WEIGHT; CANCER STEM CELL; CELL PROLIFERATION; CHEMISTRY; CONFIDENCE INTERVAL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; FLOW CYTOMETRY; PATHOLOGY; TUMOR CELL LINE; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; BODY WEIGHT; BONE MARROW; CAMPTOTHECIN; CELL LINE, TUMOR; CELL PROLIFERATION; CONFIDENCE INTERVALS; DNA TOPOISOMERASES, TYPE I; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; HUMANS; INHIBITORY CONCENTRATION 50; MALE; MICE; MICE, INBRED BALB C; NAPHTHYRIDINES; NEOPLASTIC STEM CELLS; TOPOTECAN; WEIGHT LOSS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 55749097609     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0568     Document Type: Article

References (63)

1. Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer 2006;6:789-802.
2. Giles I, Sharma RP. Topoisomerase enzymes as therapeutic targets for cancer chemotherapy. Med Chem 2005;1:383-94.
3. Tse-Dinh Y-C, Kirkegaard K, Wang JC. Covalent bonds between protein and DNA: formation of phosphotyrosine linkage between certain DNA topoisomerases and DNA. J Biol Chem 1980;255:5560-5.
4. Wang JC. DNA Topoisomerases as targets of therapeutics: an overview. In: Liu LF, editor. Advances in pharmacology. Vol. 29A. New York: Academic Press; 1994. p. 1-19.
5. Pommier Y, Barcelo JM, Rao VA, et al. Repair of topoisomerase I-mediated DNA damage. Prog Nucleic Acid Res Mol Biol 2006;8:179-229.
6. Leppard JB, Champoux JJ. Human DNA topoisomerase I: relaxation, roles and damage control. Chromosoma 2005;114:75-85.
7. Dean FB, Bullock P, Murakami Y, Wobbe CR, Weissback L, Hurwitz J. Simian virus 40 (SC40) DNA replication: SV40 large T antigen unwinds DNA containing the SV40 origin of replication. Proc Natl Acad Sci U S A 1987;84:16-20.
8. Dean FB, Borowiec JA, Ishimi Y, Deb S, Tegtmyer P, Hurwitz J. Simian virus 40 large tumor antigen requires three core replication origin domains for DNA unwinding and replication in vivo. Proc Natl Acad Sci U S A 1987;84:8267-71.
9. Brill SJ, DiNardo S, Voelkel-Meiman K, Sternglanz R. Need for DNA topoisomerase activity as a swivel for DNA replication for transcription of ribosomal RNA. Nature 1987;326:414-6.
10. Goto T, Wang JC. Cloning of yeast TOP1, the gene encoding DNA topoisomerase I, and construction of mutants defective in both DNA topoisomerase I and topoisomerase II. Proc Natl Acad Sci U S A 1985;82:7178-82.
11. Ishimi Y, Sugasawa K, Hanaoka F, Eki T, Hurwitz J. Topoisomerase II plays an essential role as a swivelase in the late stage of SV40 chromosome replication in vitro. J Biol Chem 1992;267:462-6.
12. Sundin O, Varshavsky A. Terminal stages of SV40 DNA replication proceed via multiply intertwined catenated dimers. Cell 1980;21:103-14.
13. Sundin O, Varshavsky A. Arrest of segregation leads to accumulation of highly intertwined catenated dimers. Cell 1981;25:659-69.
14. Pruss GJ, Drlica K. DNA supercoiling and prokaryotic transcription. Cell 1989;56:521-3.
15. Halligan BD, Davis JL, Edwards KA, Liu LF. Intra- and inter-molecular strand transfer by HeLa DNA topoisomerase I. J Biol Chem 1982;257:3995-4000.
16. Bullock P, Champoux JJ, Botchan M. Association of crossover points with topoisomerase I cleavage sites: a model for non-homologous recombination. Science 1985;230:954-8.
17. Garg LC, DiAngelo S, Jacob ST. Role of DNA topoisomerase I in the transcription of supercoiled rRNA gene. Proc Natl Acad Sci U S A 1987;84:3185-8.
18. Stewart AF, Schutz G. Camptothecin-induced in vivo induced topoisomerase cleavages in the transcriptionally active tyrosine aminotransferase gene. Cell 1987;50:1109-17.
19. Zhang H, Wang JC, Liu LF. Involvement of DNA topoisomerase I in the transcription of human ribosomal RNA genes. Proc Natl Acad Sci U S A 1988;85:1060-4.
20. Kreuzer KN, Cozzarelli NR. Escherichia coli mutants thermosensitive for deoxyribonucleic acid gyrase subunit A: effects on deoxyribonucleic acid replication, transcription, and bacterial growth. J Bacteriol 1979;140:424-35.
21. Drlica K, Franco RJ. Inhibitors of DNA topoisomerases. Biochemistry 1988;27:2252-9.
22. Liu LF. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 1989;58:351-75.
23. Wang JC. DNA topoisomerases. Annu Rev Biochem 1985;54:665-97.
24. Wang JC, Caron PR, Kim RA. The role of DNA topoisomerases in recombination and genome stability: a double-edged sword? Cell 1990;62:403-6.
25. Pommier Y, Tanizawa A, Kohn KW. Mechanisms of topoisomerase I inhibition by anticancer drugs. In: Liu LF, editor. Advances in pharmacology. Vol. 29B. New York: Academic Press; 1994. p. 73-92.
26. D'Arpa P, Beardmore C, Liu LF. Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. Cancer Res 1990;50:6919-24.
27. Hsiang YH, Lihou MG, Liu LF. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 1989;49:5077-82.
28. 2 arrest: altered regulation of p34cdc2/cyclin B. Cancer Res 1992;52:1823-9.
29. Li T-K, Liu LF. Tumor cell death induced by topoisomerase-targeting drugs. Annu Rev Pharmacol Toxicol 2001;41:53-77.
30. Coleman LW, Rohr LR, Bronstein IB, Holden JA. Human DNA topoisomerase I: an anticancer drug target present in human sarcomas. Hum Pathol 2002;33:599-607.
31. Lynch BJ, Komaromy-Hiller G, Bronstein IB, Holden JA. Expression of DNA topoisomerase I, DNA topoisomerase II-α and p53 in metastatic malignant melanoma. Hum Pathol 1998;29:1240-5.
32. Desai SD, Zhang H, Rodriguez-Bauman A, et al. Transcription-dependent degradation of topoisomerase I-DNA covalent complexes. Mol Cell Biol 2003;23:2341-50.
33. Desai SD, Liu LF, Vazquez-Abad D, D'Arpa P. Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin. J Biol Chem 1997;272:24159-64.
34. Beidler DR, Cheng YC. Camptothecin induction of a time- and concentration-dependent decrease of topoisomerase I and its implication in camptothecin activity. Mol Pharmacol 1995;47:907-14.
35. Desai SD, Li TK, Rodriguez-Bauman A, Rubin EH, Liu LF. Ubiquitin-26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells. Cancer Res 2001;61:5926-32.
36. Mao Y, Sun M, Desai SD, Liu LF. SUMO-1conjugat ion to topoisomerase I: a possible repair response to topoisomerase-mediated DNA damage. Proc Natl Acad Sci U S A 2000;97:4046-51.
37. Adams DJ, Dewhirst MW, Flowers JL, et al. Camptothecin analogs with enhanced antitumor activity at acidic pH. Cancer Chemother Pharmacol 2000;46:263-71.
38. Hertzberg RP, Caranfa MJ, Holden KG, et al. Modification of the hydroxyl lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J Med Chem 1989;32:715-20.
39. Chu X, Kato Y, Sugiyama Y. Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rates. Cancer Res 1997;57:1934-8.
40. Schellens JHM, Melirpaard M, Scheper RJ, et al. Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Ann N Y Acad Sci 2000;922:188-94.
41. Beretta GL, Perego P, Zunino F. Mechanisms of cellular resistance to camptothecins. Curr Med Chem 2006;13:3291-305.
42. Maliepaard M, van Gastelen MA, Tohgo A, et al. Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918. Clin Cancer Res 2001;7:935-41.
43. Yang CH, Schneider E, Kuo ML, Volk EL, Rocchi E, Chen YC. BCRP/ MXR/ABCP expression in topotecan-resistant human breast carcinoma cells. Biochem Pharmacol 2000;60:831-7.
44. Janin YL, Croisy A, Rious JL, Bisagni E. Synthesis and evaluation of new 6-amino-substituted benzo[c]phenanthridine derivatives. J Med Chem 1993;36:3686-92.
45. Ruchelman AL, Singh SK, Wu XH, et al. Diaza- and triazachrysenes: potent topoisomerase-targeting agents with exceptional antitumor activity against the human tumor xenograft MDA-MB-435. Bioorg Med Chem Lett 2002;12:3333-6.
46. Ruchelman AL, Singh SK, Wu X, et al. 5H-dibenzo[c,h]naphthyridin- 6-ones: novel topoisomerase I-targeting anticancer agents with potent cytotoxic activity. Bioorg Med Chem 2003;11:2061-73.
47. Li TK, Houghton PJ, Desai SD, et al. Characterization of ARC-111 as a novel topoisomerase I-targeting anticancer drug. Cancer Res 2003;63:8400-7.
48. Ruchelman AL, Houghton PJ, Zhou N, Liu A, Liu LF, LaVoie EJ. 5-(2-Aminothyl)dibenzo[c,h]naphthyridin-6-ones: variation of N-alkyl substituents modulates sensitivity to efflux transporters associated with multidrug resistance. J Med Chem 2005;48:792-804.
49. Kurtzberg L, Battle T, Rouleau C, et al. Bone marrow and tumor line cytotoxicity and human tumor xenograft efficacy of non-camptothecin and camptothecin topoisomerase I inhibitors. Proc Am Assoc Cancer Res 2007;48:Abstract 771.
50. Pessina A. Application of the CFU-GM assay to predict acute drug-induced neutropenia: an international blind trial to validate a prediction model for the maximum tolerated dose (MTD) of myelosuppressive xenobiotics. Toxicol Sci 2003;75:355-67.
51. Masubuchi N. A Predictive model of human myelotoxicity using five camptothecin derivatives and the in vitro colony-forming unit granulocyte/ macrophage assay. Clin Cancer Res 2004;10:6722-31.
52. Erickson-Miller C. Differential toxicity of camptothecin, topotecan and 9-aminocamptothecin to human, canine, and murine myeloid progenitors (CFU-GM) in vitro. Cancer Chemother Pharmacol 1997;39:467-72.
53. Cailleau R, Young R, Olive M, Reeves WJ, Jr. Breast tumor cell lines from pleural effusion. J Natl Cancer Inst 1974;53:661-74.
54. Brattain MG, Fine WD, Mahnaz-Khaled F, Thompson J, Brattain DE. Heterogeneity of malignant cells from a human colonic carcinoma. Cancer Res 1981;41:1751-6.
55. Fogh J, editor. Human tumor cells in vitro 43: New York: Plenum Press; 1975. p. 115-59.
56. Matsuoka Y, Moore GE, Yagi Y, Pressman D. Production of free light chains of immunoglobulin by a haematopoietic cell line derived from a patient with multiple myeloma. Proc Soc Exp Biol Med 1967;125:1246-50.
57. Banks-Schlegel SP, Gazdar AF, Harris CG. Intermediate filament and cross-linked envelope expression in human lung tumor cell lines. Cancer Res 1985;45:1187-97.
58. Eagle H. Propagation in a fluid medium of a human epidermoid carcinoma strain KB. Proc Soc Exp Biol 1955;89:362-4.
59. Fojo A, Akiyama S, Gottesman MM, Pastan I. Reduced drug accumulation in multiply drug-resistant human KB carcinoma cell lines. Cancer Res 1985;45:3002-7.
60. Shen DW, Fojo A, Chin JE, et al. Human multidrug-resistant cell lines: increased mdr1expression can precede gene amplification. Science 1986;232:643-5.
61. Mi Z, Burke TG. Marked interspecies variations concerning the interactions of camptothecin with serum albumins: a frequency-domain fluorescence spectroscopic study. Biochemistry 1994;33:12540-5.
62. Teicher BA. Next generation topoisomerase I inhibitors: rationale and biomarker strategies. Biochem Pharmacol 2008;75:1262-71.
63. Meng F, Nguyen XT, Cai X, Duan J, Matteucci M, Hart CP. ARC-111 inhibits hypoxia-mediated hypoxia-inducible factor-1α accumulation. Anticancer Drugs 2007;18:435-45.